title: Therapeutic compounds: patent evaluation of WO2011011652A1.
abstract: A series of sulfonamide derivatives, incorporating azabicyclo[3.2.1]octane and phenyl-propyl scaffolds, were prepared by a succession of original steps. The compounds are claimed to act as antagonists of the C-C chemokine receptor 5 (CCR5) involved in the entry of HIV-1 to cells, but only semi-quantitative antiviral data are provided. HIV entry inhibitors, including CCR5 antagonists, are clinically used for the treatment of this viral infection; the compounds claimed in the patent, possessing a new and original scaffold, seem to be of interest for developing novel antiviral agents belonging to this class.
authors.affiliation: University of Florence, Dipartimento di Chimica , Via della Lastruccia 3, Rm 188, 50019 Sesto Fiorentino, Florence, Italy. claudiu.supuran@unifi.it
authors.forename: Claudiu T
authors.initials: CT
authors.lastname: Supuran
mesh_terms: D000998:Antiviral Agents / Q000138:chemical synthesis / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D007202:Indicators and Reagents; D010330:Patents as Topic; D013449:Sulfonamides / Q000138:chemical synthesis*
chemical_list: D000998:Antiviral Agents; D065100:CCR5 Receptor Antagonists; D023581:HIV Fusion Inhibitors; D007202:Indicators and Reagents; D013449:Sulfonamides